Results 61 to 70 of about 8,597,475 (170)

Current Landscape and Future Perspectives of Diabetic Retinopathy Therapy: Pharmacological Targets, Precision Laser Technology, and Clinical Evidence

MedComm, Volume 7, Issue 7, July 2026.
Targeted biological agents targeting VEGF, integrin, dopamine D2 receptor, ROCK, and BCL‐XL have entered the clinical trial phase and deserve particular attention. The treatment paradigm has shifted toward personalized and precision medicine, positioning optimized SML as a promising adjunctive therapy.
Xinying Hu, Zhe Cha, Ao Lu, Wuping Xu, Xiaoqing Zhang, Sheng Miao, Haiwei Xu, Xuedong Xu   +7 more
wiley   +1 more source

Plain language summary of publication of the 48-week results from the PULSAR study investigating how well a new dose of aflibercept works and how safe it is for people with wet age-related macular degeneration

Therapeutic Advances in Ophthalmology
What is this summary about? • This is a summary of a publication about the PULSAR study, which was published in The Lancet scientific journal. • Wet age-related macular degeneration (or AMD) is a long-term eye disease in which abnormal blood vessels grow
Paolo Lanzetta, Jean-François Korobelnik, Jeffrey S. Heier, Sergio Leal, Frank G. Holz, William Lloyd Clark, David Eichenbaum, Tomohiro Iida, Xiaodong Sun, Alyson J. Berliner, Andrea Schulze, Thomas Schmelter, Ursula Schmidt-Ott, Xin Zhang, Robert Vitti, Karen W. Chu, Kimberly Reed, Rohini Rao, Rafia Bhore, Yenchieh Cheng, Tien Y. Wong   +20 more
doaj   +1 more source

Intravitreal Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration

Ophthalmology
Purpose To report the efficacy, durability, and safety of intravitreal aflibercept 8 mg versus intravitreal aflibercept 2 mg every 8 weeks (2q8) in patients with neovascular age-related macular degeneration (nAMD) through 96 weeks, PULSAR ( ClinicalTrials.gov identifier, NCT04423718).
Korobelnik J. -F., Lanzetta P., Leal S., Holz F. G., Clark W. L., Eichenbaum D., Iida T., Sun X., Berliner A. J., Schulze A., Zhao M., Schmelter T., Schmidt-Ott U., Zhang X., Morgan-Warren P., Hasanbasic Z., Vitti R., Chu K. W., Reed K., Bhore R., Cheng Y., Bai Z., Hirshberg B., Yancopoulos G. D., Wong T. Y.   +24 more
openaire   +1 more source

Studying When to Add Biological Therapy to Cytotoxic Therapy in Advanced Cancer Care Using Real World Data: How to Avoid Design Choices That Generate Immortal Time

Cancer Medicine, Volume 15, Issue 6, June 2026.
ABSTRACT Background Since real‐world data lack information on treatment assignment (usually the only information available is treatment prescription/administration) and early outcomes can happen in advanced cancer, some design choices may introduce immortal time due to selection or due to treatment strategy misclassification.
Xabier Garcia‐Albeniz, Julia Vila‐Guilera, Manuel Zamparini, Helena Oliveres, Vicente Alonso‐Orduna, Jaime Feliu, Ana Fernández‐Montes, Marta Martín‐Richard, Elisa Gálvez‐Munoz, Ana Ruiz‐Casado, Alfonso Yubero‐Esteban, Jorge Aparicio, Julia Alcaide‐Garcia, Javier Gallego Plazas, Carlos Fernandez‐Martos, Rosa Gallego‐Sanchez, Mónica Guillot Morales, Rubén Leno, Francis Esposito, Sandra Lopez‐Prades, Míriam Cuatrecasas, Barbra A. Dickerman, Joan Maurel   +22 more
wiley   +1 more source

Image analysis method for measurement and prediction of intra‐matrix IgG diffusion

Biotechnology Progress, Volume 42, Issue 3, May/June 2026.
Experimental and image analysis workflow for b‐IgG diffusion in hyaluronic acid (HA) matrix. Abstract Measurement and imaging of intra‐matrix protein therapeutics diffusion is important due to the emergence of injectable biologics currently in various stages of research and clinical testing.
Riya Debbarma, Antonio C. F. dos Santos, Michael Ladisch   +2 more
wiley   +1 more source

Early real-world anatomic response and interval extension after switching to aflibercept 8 mg in previously treated eyes with neovascular AMD or pachychoroid-related macular neovascularization

AJO International
Purpose: To evaluate early anatomic response and treatment-interval behavior after switching to aflibercept 8 mg in previously treated eyes with neovascular AMD or pachychoroid macular neovascularization under routine clinical practice.
Maria Emfietzoglou, Solomon Frances, Alexander Charonis   +2 more
doaj   +1 more source

Tumor Anti‐Angiogenesis Therapy and Its Influence on Immune Cell Function in the Tumor Microenvironment

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Vascular normalization, one promising anti‐angiogenic strategy, has the potential to enhance vascular perfusion and elevate the infiltration of immune cells into tumors by rectifying aberrant tumor blood vessels. This results in the enhancement of immunotherapy.
Yu Tang, Yuyan Ding, LiPing Wang, Yujiao Yang, Youwei Han, Peng Zhou, Huiheng Qu, Kaiyuan Deng, Jiazeng Xia   +8 more
wiley   +1 more source

The Contribution to the Assignment of Defined Daily Dose (DDD) to Antineoplastic Drugs of the Italian Working Group on DDD

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 5, May 2026.
ABSTRACT Purpose To report the experience of the Italian Working Group on DDD (Ita‐DDD‐wg) in assigning DDDs to a list of antineoplastic agents. Methods Active substances from the ATC L01 group with no assigned DDD and reimbursed at least once during 2021 by the Italian Healthcare Service were identified.
Angela Boccia, Giulia Hyeraci, Anna Girardi, Rosa Gini, Gianluca Trifirò, Ylenia Ingrasciotta, Andrea Spini, Valentina Ientile, Elisabetta Poluzzi, Giampiero Mazzaglia, Ippazio Cosimo Antonazzo, Casula Manuela, Elena Tragni, Olivia Leoni, Arianna Mazzone, Michele Ercolanoni, Martina Zanforlini, Ursula Kirchmayer, Belleudi Valeria, Marco Finocchietti, Francesco Barone‐Adesi, Giuseppe Roberto   +21 more
wiley   +1 more source

Early high‐dose aflibercept 8 mg clinical outcomes in wet age‐related macular degeneration patients resistant to aflibercept 2 mg or faricimab

Acta Ophthalmologica, EarlyView.
Pinja Sutinen, Idan Hecht, Raimo Tuuminen   +2 more
wiley   +1 more source

Aflibercept 8 mg versus faricimab for macular oedema due to retinal vein occlusion: a systematic review and network meta-analysis

Aim To indirectly evaluate the comparative efficacy and safety of aflibercept 8 mg and faricimab in treating retinal vein occlusion (RVO)-associated macular oedema.
Zhengyang Liu, Sujan A Surendran, Elaine W Chong   +2 more
core   +1 more source